Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Carcinoma, Hepatocellular 8Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Lymphoma, Extranodal NK-T-Cell 6Locally Advanced Rectal Cancer 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hemangiosarcoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disorders of Sex Development × spartalizumab × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡